Cancer therapy: Targeting the poison within

Cell Cycle

Volumn 13, Issue 15, 2014, Pages 2330-2333

  Smits, Veronique A J ^a   Gillespie, David A ^b  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Cancer therapy; DNA damage; DNA repair; MTH1; Oxidative stress

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; MTH1 PROTEIN; NUCLEOTIDE PYROPHOSPHATASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 8-OXODGTPASE; CRIZOTINIB; DNA LIGASE; ENZYME INHIBITOR; PHOSPHATASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; EXCISION REPAIR; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; OXIDATIVE STRESS; SHORT SURVEY; SINGLE STRANDED DNA BREAK; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA REPAIR ENZYMES; DNA, NEOPLASM; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; PYRAZOLES; PYRIDINES;

EID: 84905906163     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.29756     Document Type: Short Survey

References (16)

1. Horne SD, Stevens JB, Abdallah BY, Liu G, Bremer SW, Ye CJ, Heng HH. Why imatinib remains an exception of cancer research. J Cell Physiol 2013; 228:665-70; PMID:23018746; http://dx.doi.org/10.1002/jcp.24233
2. Bucheit AD, Davies MA. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol 2014; 87:381-9; PMID:24291778; http://dx.doi.org/10.1016/j.bcp.2013.11.013
3. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; http://dx.doi.org/10.1038/nature03445
4. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4:814-9; PMID:15510162; http://dx.doi.org/10.1038/ nrc1457
5. van Leeuwen IM. Cyclotherapy: opening a therapeutic window in cancer treatment. Oncotarget 2012; 3:596-600; PMID:22711025
6. Blagosklonny MV. "Targeting the absence" and therapeutic engineering for cancer therapy. Cell Cycle 2008; 7:1307-12; PMID:18487952; http://dx.doi.org/10.4161/cc.7.10.6250
7. Mancias JD, Kimmelman AC. Targeting autophagy addiction in cancer. Oncotarget 2011; 2:1302-6; PMID:22185891
8. Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Ström CE, Svensson LM, Schultz N, Lundbäck T, Einarsdottir BO, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature 2014; 508:215-21; PMID:24695224; http://dx.doi.org/10.1038/nature13181
9. Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Göktürk C, Sanjiv K, Strömberg K, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 2014; 508:222-7; PMID:24695225; http://dx.doi.org/10.1038/nature13194
10. Rai P, Young JJ, Burton DG, Giribaldi MG, Onder TT, Weinberg RA. Enhanced elimination of oxidized guanine nucleotides inhibits oncogenic RAS-induced DNA damage and premature senescence. Oncogene 2011; 30:1489-96; PMID:21076467; http://dx.doi.org/10.1038/onc.2010.520
11. Sakumi K, Furuichi M, Tsuzuki T, Kakuma T, Kawabata S, Maki H, Sekiguchi M. Cloning and expression of cDNA for a human enzyme that hydrolyzes 8-oxo-dGTP, a mutagenic substrate for DNA synthesis. J Biol Chem 1993; 268:23524-30; PMID:8226881
12. Walsh AB, Dhanasekaran M, Bar-Sagi D, Kumar CC. SCH 51344-induced reversal of RAS-transformation is accompanied by the specific inhibition of the RAS and RAC-dependent cell morphology pathway. Oncogene 1997; 15:2553-60; PMID:9399643; http://dx.doi.org/10.1038/sj.onc.1201424
13. Tsuzuki T, Egashira A, Kura S. Analysis of MTH1 gene function in mice with targeted mutagenesis. Mutat Res 2001; 477:71-8; PMID:11376688; http://dx.doi.org/10.1016/S0027-5107(01)00108-7
14. Speina E, Arczewska KD, Gackowski D, Zielińska M, Siomek A, Kowalewski J, Oliński R, Tudek B, Kuśmierek JT. Contribution of hMTH1 to the maintenance of 8-oxoguanine levels in lung DNA of non-small-cell lung cancer patients. J Natl Cancer Inst 2005; 97:384-95; PMID:15741575; http://dx.doi.org/10.1093/jnci/dji058
15. Kennedy CH, Cueto R, Belinsky SA, Lechner JF, Pryor WA. Overexpression of hMTH1 mRNA: a molecular marker of oxidative stress in lung cancer cells. FEBS Lett 1998; 429:17-20; PMID:9657375; http://dx.doi.org/10.1016/S0014-5793(98) 00505-5
16. Okamoto K, Toyokuni S, Kim WJ, Ogawa O, Kakehi Y, Arao S, Hiai H, Yoshida O. Overexpression of human mutT homologue gene messenger RNA in renal-cell carcinoma: evidence of persistent oxidative stress in cancer. Int J Cancer 1996; 65:437-41; PMID:8621223; http://dx.doi.org/10.1002/(SICI)1097-0215(19960208)65: 4〈437::AID-IJC7〉3.0.CO;2-Y